Chongqing Lummy Pharmaceutical Total Liabilities
Chongqing Lummy Pharmaceutical total liabilities. Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has total liabilities worth CN¥910.32 Million CNY (≈ $133.21 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Chongqing Lummy Pharmaceutical's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chongqing Lummy Pharmaceutical (2006–2024)
Total liabilities of Chongqing Lummy Pharmaceutical from 2006 to 2024. This chart illustrates how Chongqing Lummy Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore Chongqing Lummy Pharmaceutical strategic investment ratio to see how much of total assets are deployed in long-term investments.
Chongqing Lummy Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AVALON TECHNOLOGIES LTD
NSE:AVALON
|
India | Rs5.43 Billion |
|
Kirloskar Brothers Limited
NSE:KIRLOSBROS
|
India | Rs-24.76 Billion |
|
Galecto Inc
NASDAQ:GLTO
|
USA | $25.18 Million |
|
Ganfeng Lithium Co. Ltd
F:39EA
|
Germany | €65.69 Billion |
|
FADU Inc.
KQ:440110
|
Korea | ₩47.55 Billion |
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
China | CN¥4.71 Billion |
|
Bestway Marine & Energy Technology Co Ltd
SHE:300008
|
China | CN¥4.09 Billion |
|
Herbalife Nutrition Ltd
F:HOO
|
Germany | €3.30 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Chongqing Lummy Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300006 current and non-current assets.
Liquidity & Leverage Metrics
Chongqing Lummy Pharmaceutical Total Liabilities Ratios Explained
Chongqing Lummy Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chongqing Lummy Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual total liabilities of Chongqing Lummy Pharmaceutical from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥972.47 Million ≈ $142.30 Million |
+26.51% |
| 2023-12-31 | CN¥768.71 Million ≈ $112.49 Million |
-11.64% |
| 2022-12-31 | CN¥870.02 Million ≈ $127.31 Million |
+21.74% |
| 2021-12-31 | CN¥714.65 Million ≈ $104.58 Million |
-62.70% |
| 2020-12-31 | CN¥1.92 Billion ≈ $280.40 Million |
+3.71% |
| 2019-12-31 | CN¥1.85 Billion ≈ $270.38 Million |
+30.42% |
| 2018-12-31 | CN¥1.42 Billion ≈ $207.31 Million |
+39.24% |
| 2017-12-31 | CN¥1.02 Billion ≈ $148.89 Million |
+25.63% |
| 2016-12-31 | CN¥809.85 Million ≈ $118.51 Million |
-42.68% |
| 2015-12-31 | CN¥1.41 Billion ≈ $206.75 Million |
+15.15% |
| 2014-12-31 | CN¥1.23 Billion ≈ $179.54 Million |
+16.14% |
| 2013-12-31 | CN¥1.06 Billion ≈ $154.59 Million |
+48.12% |
| 2012-12-31 | CN¥713.21 Million ≈ $104.37 Million |
+69.48% |
| 2011-12-31 | CN¥420.81 Million ≈ $61.58 Million |
+30.52% |
| 2010-12-31 | CN¥322.42 Million ≈ $47.18 Million |
+150.82% |
| 2009-12-31 | CN¥128.55 Million ≈ $18.81 Million |
-1.70% |
| 2008-12-31 | CN¥130.77 Million ≈ $19.14 Million |
+22.47% |
| 2007-12-31 | CN¥106.78 Million ≈ $15.62 Million |
+75.86% |
| 2006-12-31 | CN¥60.72 Million ≈ $8.88 Million |
-- |
About Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more